Kane Biotech Inc Market Cap ($4.60 Million)
Market Cap & Net Worth: Kane Biotech Inc (KNE)
Kane Biotech Inc market cap. Kane Biotech Inc (V:KNE) has a market capitalization of $4.60 Million (CA$6.36 Million) as of November 3, 2026. Listed on the V stock exchange, this Canada-based company holds position #28689 globally and #1268 in its home market, demonstrating a 16.67% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kane Biotech Inc's stock price CA$0.04 by its total outstanding shares 181856565 (181.86 Million). Also see KNE cash flow conversion for how efficiently the company converts equity into cash flow.
Kane Biotech Inc Market Cap History (2015–2026)
Kane Biotech Inc market cap history from 2015 to 2026. Data shows change from $32.89 Million to $4.60 Million (-16.30% CAGR). Check KNE stock price and chart for real-time trading data and today's change.
Kane Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kane Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore KNE shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
12.30x
Kane Biotech Inc's market cap is 12.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $19.73 Million | $244.76K | -$2.55 Million | 80.62x | N/A |
| 2017 | $13.16 Million | $1.04 Million | -$2.79 Million | 12.71x | N/A |
| 2018 | $11.84 Million | $506.27K | -$3.26 Million | 23.39x | N/A |
| 2019 | $18.42 Million | $1.69 Million | -$960.18K | 10.88x | N/A |
| 2020 | $18.42 Million | $1.34 Million | -$3.72 Million | 13.73x | N/A |
| 2021 | $21.05 Million | $1.61 Million | -$4.60 Million | 13.09x | N/A |
| 2022 | $11.84 Million | $2.67 Million | -$3.89 Million | 4.44x | N/A |
| 2023 | $10.52 Million | $148.98K | -$5.03 Million | 70.64x | N/A |
| 2024 | $14.47 Million | $2.08 Million | $6.10 Million | 6.95x | 2.37x |
| 2025 | $5.26 Million | $427.87K | -$2.72 Million | 12.30x | N/A |
Competitor Companies of KNE by Market Capitalization
Companies near Kane Biotech Inc in the global market cap rankings as of November 3, 2026. Also see Kane Biotech Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Kane Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Kane Biotech Inc (2015–2026)
Market capitalization of Kane Biotech Inc from 2015 to today. Between 2015 and today, Kane Biotech Inc's market cap moved from $32.89 Million to $ 4.60 Million, with a yearly change of -16.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$4.60 Million | -12.50% |
| 2025 | CA$5.26 Million | -63.64% |
| 2024 | CA$14.47 Million | +37.50% |
| 2023 | CA$10.52 Million | -11.11% |
| 2022 | CA$11.84 Million | -43.75% |
| 2021 | CA$21.05 Million | +14.29% |
| 2020 | CA$18.42 Million | 0.00% |
| 2019 | CA$18.42 Million | +55.56% |
| 2018 | CA$11.84 Million | -10.00% |
| 2017 | CA$13.16 Million | -33.33% |
| 2016 | CA$19.73 Million | -40.00% |
| 2015 | CA$32.89 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Kane Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.60 Million USD |
| MoneyControl | $4.60 Million USD |
| MarketWatch | $4.60 Million USD |
| marketcap.company | $4.60 Million USD |
| Reuters | $4.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the … Read more